|
|
 | | | |
- close
- close
- close
- close
These excerpts taken from the GTF 10-K filed Mar 31, 2009. PatentsCytomedix’s patent strategy, designed to maximize value, seeks to (i) assist the Company in establishing significant market positions for its products, (ii) attract strategic partners for collaborative research, development, marketing, distribution, or other agreements, which could likely include milestone payments to the Company, and (iii) generate revenue streams through licensing agreements. Cytomedix’s current patent portfolio consists of more than 30 domestic and international patents that generally fall into the following families:
The above patent families encompass the Company’s AutoloGelTM System, CT-112 anti-inflammatory peptide, homologous growth factors, wound-healing biomarkers, and several other potential therapies. Cytomedix is continually assessing new opportunities to create or in-license other intellectual property assets. In 2009, the Company is planning to file at least several new provisional patent applications covering new inventions or improvements to existing patents. 8 PatentsCytomedix’s patent strategy, designed to maximize value, seeks to (i) assist the Company in establishing significant market positions for its products, (ii) attract strategic partners for collaborative research, development, marketing, distribution, or other agreements, which could likely include milestone payments to the Company, and (iii) generate revenue streams through licensing agreements. Cytomedix’s current patent portfolio consists of more than 30 domestic and international patents that generally fall into the following families:
The above patent families encompass the Company’s AutoloGelTM System, CT-112 anti-inflammatory peptide, homologous growth factors, wound-healing biomarkers, and several other potential therapies. Cytomedix is continually assessing new opportunities to create or in-license other intellectual property assets. In 2009, the Company is planning to file at least several new provisional patent applications covering new inventions or improvements to existing patents. 8 PatentsCytomedix’s patent strategy, designed to maximize value, seeks to (i) assist the Company in establishing significant market positions for its products, (ii) attract strategic partners for collaborative research, development, marketing, distribution, or other agreements, which could likely include milestone payments to the Company, and (iii) generate revenue streams through licensing agreements. Cytomedix’s current patent portfolio consists of more than 30 domestic and international patents that generally fall into the following families:
The above patent families encompass the Company’s AutoloGelTM System, CT-112 anti-inflammatory peptide, homologous growth factors, wound-healing biomarkers, and several other potential therapies. Cytomedix is continually assessing new opportunities to create or in-license other intellectual property assets. In 2009, the Company is planning to file at least several new provisional patent applications covering new inventions or improvements to existing patents. 8 PatentsCytomedix’s patent strategy, designed to maximize value, seeks to (i) assist the Company in establishing significant market positions for its products, (ii) attract strategic partners for collaborative research, development, marketing, distribution, or other agreements, which could likely include milestone payments to the Company, and (iii) generate revenue streams through licensing agreements. Cytomedix’s current patent portfolio consists of more than 30 domestic and international patents that generally fall into the following families:
The above patent families encompass the Company’s AutoloGelTM System, CT-112 anti-inflammatory peptide, homologous growth factors, wound-healing biomarkers, and several other potential therapies. Cytomedix is continually assessing new opportunities to create or in-license other intellectual property assets. In 2009, the Company is planning to file at least several new provisional patent applications covering new inventions or improvements to existing patents. 8 | ||||||||||||||||||||||||||||||||||||||||||||||||
PatentsCytomedix’s patent strategy, designed to maximize value, seeks to (i) assist the Company in establishing significant market positions for its products, (ii) attract strategic partners for collaborative research, development, marketing, distribution, or other agreements, which could likely include milestone payments to the Company, and (iii) generate revenue streams through licensing agreements. Cytomedix’s current patent portfolio consists of more than 30 domestic and international patents that generally fall into the following families:
The above patent families encompass the Company’s AutoloGelTM System, CT-112 anti-inflammatory peptide, homologous growth factors, wound-healing biomarkers, and several other potential therapies. Cytomedix is continually assessing new opportunities to create or in-license other intellectual property assets. In 2009, the Company is planning to file at least several new provisional patent applications covering new inventions or improvements to existing patents. 8 | ||||||||||||||||||||||||||||||||||||||||||||||||
PatentsCytomedix’s patent strategy, designed to maximize value, seeks to (i) assist the Company in establishing significant market positions for its products, (ii) attract strategic partners for collaborative research, development, marketing, distribution, or other agreements, which could likely include milestone payments to the Company, and (iii) generate revenue streams through licensing agreements. Cytomedix’s current patent portfolio consists of more than 30 domestic and international patents that generally fall into the following families:
The above patent families encompass the Company’s AutoloGelTM System, CT-112 anti-inflammatory peptide, homologous growth factors, wound-healing biomarkers, and several other potential therapies. Cytomedix is continually assessing new opportunities to create or in-license other intellectual property assets. In 2009, the Company is planning to file at least several new provisional patent applications covering new inventions or improvements to existing patents. 8 | ||||||||||||||||||||||||||||||||||||||||||||||||
EXCERPTS ON THIS PAGE:
RELATED TOPICS for GTF: |
| |||||||
